
Chinese General Practice ›› 2026, Vol. 29 ›› Issue (33): 4922-4927.DOI: 10.12114/j.issn.1007-9572.2025.0279
• Focus Groups Studies·Children and Adolescents • Previous Articles Next Articles
Received:2025-08-29
Revised:2026-01-04
Published:2026-11-20
Online:2026-10-21
Contact:
DU Kaixian
通讯作者:
杜开先
作者简介:作者贡献:
刘玉提出研究思路,负责研究方案的实施,数据收集及整理,统计分析,文章构思与设计,撰写论文;孔丽娜负责研究可行性的分析;杜开先、关静、陈豪、李林、李肖、宋盼盼、彭艳华负责实施具体试验;杜开先负责协调、文章最终版本的修订与审校,监督管理,对文章整体负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2025.0279
| 组别 | 例数 | 性别(男/女) | 体质量( | 起病年龄[M(P25,P75),月] | 起病至确诊时间[M(P25,P75),月] | 首次发病诱因(有/无) | 发作形式改变(有/无) | 遗传病因(有/无) | 结构病因(有/无) |
|---|---|---|---|---|---|---|---|---|---|
| 耐药组 | 94 | 52/42 | 12.84±7.45 | 9.00(4.88,30.50) | 0.70(0.20,3.00) | 13/81 | 31/63 | 42/52 | 33/61 |
| 非耐药组 | 156 | 83/73 | 15.09±6.73 | 24.50(9.18,52.00) | 1.45(0.30,7.00) | 45/111 | 25/131 | 46/110 | 31/125 |
| 检验统计量值 | 0.106 | 2.452a | 3.648b | 2.789b | 7.423 | 9.698 | 5.936 | 7.148 | |
| P值 | 0.745 | 0.015 | <0.001 | 0.060 | 0.006 | 0.002 | 0.015 | 0.008 | |
| 组别 | 代谢病因(有/无) | 感染病因(有/无) | 免疫病因(有/无) | 病因未明(有/无) | 治疗前发作持续时间[M(P25,P75),min] | 治疗前发作次数[M(P25,P75),次] | 癫痫持续状态(有/无) | 首次抗癫痫药效果(有/无/未用) | |
| 耐药组 | 2/92 | 0/94 | 1/93 | 19/75 | 9.00(5.00,12.25) | 17.00(3.75,52.50) | 52/42 | 12/82/0 | |
| 非耐药组 | 2/154 | 0/156 | 1/155 | 78/78 | 5.00(4.00,9.00) | 4.00(2.00,7.00) | 58/98 | 120/31/5 | |
| 检验统计量值 | 0.266 | 0.132 | 21.917 | -3.579b | -2.653b | 7.833 | 107.625 | ||
| P值 | 0.606 | 0.717 | <0.001 | <0.001 | 0.009 | 0.005 | <0.001 | ||
| 组别 | 共患病(有/无) | 发育迟缓(有/无) | 新生儿癫痫发作史(有/无) | 热性惊厥史(有/无) | 脑外伤史(有/无) | 脑感染史(有/无) | 出生异常史(有/无) | 父系家族史(有/无) | 母系家族史(有/无) |
| 耐药组 | 3/91 | 75/19 | 4/90 | 7/87 | 1/93 | 0/94 | 41/53 | 12/82 | 6/88 |
| 非耐药组 | 5/151 | 54/102 | 6/150 | 25/131 | 0/156 | 2/154 | 39/117 | 27/129 | 19/137 |
| 检验统计量值 | <0.001 | 47.924 | 0.026 | 3.868 | 1.666 | 1.215 | 9.343 | 0.919 | 2.190 |
| P值 | 0.995 | <0.001 | 0.873 | 0.049 | 0.197 | 0.270 | 0.002 | 0.338 | 0.139 |
Table 1 Comparison of general data between the two groups
| 组别 | 例数 | 性别(男/女) | 体质量( | 起病年龄[M(P25,P75),月] | 起病至确诊时间[M(P25,P75),月] | 首次发病诱因(有/无) | 发作形式改变(有/无) | 遗传病因(有/无) | 结构病因(有/无) |
|---|---|---|---|---|---|---|---|---|---|
| 耐药组 | 94 | 52/42 | 12.84±7.45 | 9.00(4.88,30.50) | 0.70(0.20,3.00) | 13/81 | 31/63 | 42/52 | 33/61 |
| 非耐药组 | 156 | 83/73 | 15.09±6.73 | 24.50(9.18,52.00) | 1.45(0.30,7.00) | 45/111 | 25/131 | 46/110 | 31/125 |
| 检验统计量值 | 0.106 | 2.452a | 3.648b | 2.789b | 7.423 | 9.698 | 5.936 | 7.148 | |
| P值 | 0.745 | 0.015 | <0.001 | 0.060 | 0.006 | 0.002 | 0.015 | 0.008 | |
| 组别 | 代谢病因(有/无) | 感染病因(有/无) | 免疫病因(有/无) | 病因未明(有/无) | 治疗前发作持续时间[M(P25,P75),min] | 治疗前发作次数[M(P25,P75),次] | 癫痫持续状态(有/无) | 首次抗癫痫药效果(有/无/未用) | |
| 耐药组 | 2/92 | 0/94 | 1/93 | 19/75 | 9.00(5.00,12.25) | 17.00(3.75,52.50) | 52/42 | 12/82/0 | |
| 非耐药组 | 2/154 | 0/156 | 1/155 | 78/78 | 5.00(4.00,9.00) | 4.00(2.00,7.00) | 58/98 | 120/31/5 | |
| 检验统计量值 | 0.266 | 0.132 | 21.917 | -3.579b | -2.653b | 7.833 | 107.625 | ||
| P值 | 0.606 | 0.717 | <0.001 | <0.001 | 0.009 | 0.005 | <0.001 | ||
| 组别 | 共患病(有/无) | 发育迟缓(有/无) | 新生儿癫痫发作史(有/无) | 热性惊厥史(有/无) | 脑外伤史(有/无) | 脑感染史(有/无) | 出生异常史(有/无) | 父系家族史(有/无) | 母系家族史(有/无) |
| 耐药组 | 3/91 | 75/19 | 4/90 | 7/87 | 1/93 | 0/94 | 41/53 | 12/82 | 6/88 |
| 非耐药组 | 5/151 | 54/102 | 6/150 | 25/131 | 0/156 | 2/154 | 39/117 | 27/129 | 19/137 |
| 检验统计量值 | <0.001 | 47.924 | 0.026 | 3.868 | 1.666 | 1.215 | 9.343 | 0.919 | 2.190 |
| P值 | 0.995 | <0.001 | 0.873 | 0.049 | 0.197 | 0.270 | 0.002 | 0.338 | 0.139 |
| 组别 | 例数 | 纤维蛋白原( | 甲状旁腺激素( | 乳酸( | 血氨( | 血同型半胱氨酸( | 铜蓝蛋白( |
|---|---|---|---|---|---|---|---|
| 耐药组 | 94 | 2.04±0.58 | 2.64±1.36 | 3.00±1.19 | 24.89±12.27 | 7.85±7.20 | 240.89±47.21 |
| 非耐药组 | 156 | 2.27±0.50 | 2.50±0.43 | 2.90±1.06 | 20.46±8.87 | 7.85±4.32 | 257.41±50.08 |
| χ2(t)值 | 3.115a | -0.981a | -0.634a | -3.053a | -0.638a | 2.581a | |
| P值 | 0.002 | 0.329 | 0.527 | 0.003 | 0.524 | 0.010 | |
| 组别 | 维生素D ( | 颅脑MRI (异常/正常) | 首次脑电图(异常/正常) | 治疗半年后脑电图(异常/正常) | 多灶性癫痫样放电(有/无) | 遗传代谢病筛查(异常/正常) | 染色体及基因检测(正常/异常/未测) |
| 耐药组 | 110.78±42.87 | 37/57 | 88/6 | 88/6 | 68/26 | 5/89 | 7/33/54 |
| 非耐药组 | 95.83±41.48 | 29/127 | 130/26 | 86/70 | 38/118 | 4/152 | 13/24/119 |
| χ2(t)值 | -2.725a | 13.025 | 5.558 | 41.068 | 55.293 | 1.283 | 13.071 |
| P值 | 0.007 | <0.001 | 0.018 | <0.001 | <0.001 | 0.257 | 0.001 |
Table 2 Comparison of laboratory test indicators between the two groups
| 组别 | 例数 | 纤维蛋白原( | 甲状旁腺激素( | 乳酸( | 血氨( | 血同型半胱氨酸( | 铜蓝蛋白( |
|---|---|---|---|---|---|---|---|
| 耐药组 | 94 | 2.04±0.58 | 2.64±1.36 | 3.00±1.19 | 24.89±12.27 | 7.85±7.20 | 240.89±47.21 |
| 非耐药组 | 156 | 2.27±0.50 | 2.50±0.43 | 2.90±1.06 | 20.46±8.87 | 7.85±4.32 | 257.41±50.08 |
| χ2(t)值 | 3.115a | -0.981a | -0.634a | -3.053a | -0.638a | 2.581a | |
| P值 | 0.002 | 0.329 | 0.527 | 0.003 | 0.524 | 0.010 | |
| 组别 | 维生素D ( | 颅脑MRI (异常/正常) | 首次脑电图(异常/正常) | 治疗半年后脑电图(异常/正常) | 多灶性癫痫样放电(有/无) | 遗传代谢病筛查(异常/正常) | 染色体及基因检测(正常/异常/未测) |
| 耐药组 | 110.78±42.87 | 37/57 | 88/6 | 88/6 | 68/26 | 5/89 | 7/33/54 |
| 非耐药组 | 95.83±41.48 | 29/127 | 130/26 | 86/70 | 38/118 | 4/152 | 13/24/119 |
| χ2(t)值 | -2.725a | 13.025 | 5.558 | 41.068 | 55.293 | 1.283 | 13.071 |
| P值 | 0.007 | <0.001 | 0.018 | <0.001 | <0.001 | 0.257 | 0.001 |
| 变量 | 赋值 |
|---|---|
| DRE | 是=1,否=0 |
| 体质量、起病年龄、治疗前发作持续时间、治疗前发作次数、纤维蛋白原、血氨、铜蓝蛋白、维生素D | 实测值 |
| 首次发病诱因、发作形式改变、遗传病因、结构病因、病因未明、首次抗癫痫药效果、发育迟缓、热性惊厥史、多灶性癫痫样放电 | 无=0,有=1 |
| 出生史、颅脑MRI、首次脑电图、治疗半年后脑电图、染色体及基因检测 | 正常=0,异常=1 |
Table 3 Variable assignment table
| 变量 | 赋值 |
|---|---|
| DRE | 是=1,否=0 |
| 体质量、起病年龄、治疗前发作持续时间、治疗前发作次数、纤维蛋白原、血氨、铜蓝蛋白、维生素D | 实测值 |
| 首次发病诱因、发作形式改变、遗传病因、结构病因、病因未明、首次抗癫痫药效果、发育迟缓、热性惊厥史、多灶性癫痫样放电 | 无=0,有=1 |
| 出生史、颅脑MRI、首次脑电图、治疗半年后脑电图、染色体及基因检测 | 正常=0,异常=1 |
| 自变量 | B | SE | Wald χ2值 | P值 | OR(95%CI) |
|---|---|---|---|---|---|
| 首次抗癫痫药效果欠佳(以有效为参照) | 2.941 | 0.415 | 50.206 | <0.001 | 18.928(8.392~42.693) |
| 治疗前发作持续时间 | 0.085 | 0.041 | 4.401 | 0.036 | 1.089(1.006~1.180) |
| 发育迟缓(以无为参照) | 1.228 | 0.418 | 8.618 | 0.003 | 3.415(1.504~7.754) |
| 多灶性癫痫样放电(以无为参照) | 1.661 | 0.415 | 16.029 | <0.001 | 5.265(2.335~11.873) |
Table 4 Multivariate Logistic stepwise regression analysis of risk factors for DRE
| 自变量 | B | SE | Wald χ2值 | P值 | OR(95%CI) |
|---|---|---|---|---|---|
| 首次抗癫痫药效果欠佳(以有效为参照) | 2.941 | 0.415 | 50.206 | <0.001 | 18.928(8.392~42.693) |
| 治疗前发作持续时间 | 0.085 | 0.041 | 4.401 | 0.036 | 1.089(1.006~1.180) |
| 发育迟缓(以无为参照) | 1.228 | 0.418 | 8.618 | 0.003 | 3.415(1.504~7.754) |
| 多灶性癫痫样放电(以无为参照) | 1.661 | 0.415 | 16.029 | <0.001 | 5.265(2.335~11.873) |
| 指标 | 最佳截断值 | 灵敏度 | 特异度 | 约登指数 | AUC | 95%CI |
|---|---|---|---|---|---|---|
| 首次抗癫痫药效果欠佳 | 0.500 | 0.872 | 0.801 | 0.673 | 0.837 | 0.783~0.890 |
| 治疗前发作持续时间长 | 8.50 min | 0.553 | 0.712 | 0.265 | 0.633 | 0.561~0.706 |
| 发育迟缓 | 0.500 | 0.798 | 0.654 | 0.452 | 0.726 | 0.661~0.791 |
| 多灶性癫痫样放电 | 0.500 | 0.723 | 0.756 | 0.480 | 0.740 | 0.675~0.805 |
| 联合指标 | 0.316 | 0.904 | 0.801 | 0.706 | 0.920 | 0.887~0.953 |
Table 5 Predictive value of high-risk factors and combined indicators for pediatric DRE
| 指标 | 最佳截断值 | 灵敏度 | 特异度 | 约登指数 | AUC | 95%CI |
|---|---|---|---|---|---|---|
| 首次抗癫痫药效果欠佳 | 0.500 | 0.872 | 0.801 | 0.673 | 0.837 | 0.783~0.890 |
| 治疗前发作持续时间长 | 8.50 min | 0.553 | 0.712 | 0.265 | 0.633 | 0.561~0.706 |
| 发育迟缓 | 0.500 | 0.798 | 0.654 | 0.452 | 0.726 | 0.661~0.791 |
| 多灶性癫痫样放电 | 0.500 | 0.723 | 0.756 | 0.480 | 0.740 | 0.675~0.805 |
| 联合指标 | 0.316 | 0.904 | 0.801 | 0.706 | 0.920 | 0.887~0.953 |
| 组别 | 例数 | 运动能区 | 个人与社会能区 | 语言能区 | 手眼协调能区 | 表现能区 | 实际推理能区c |
|---|---|---|---|---|---|---|---|
| 对照组 | 80 | 101.06±8.26 | 100.34±7.97 | 101.94±9.67 | 102.51±7.08 | 103.28±8.15 | 104.58±8.09 |
| 耐药组 | 94 | 62.20±25.37a | 60.50±28.42a | 60.20±26.74a | 58.03±29.96a | 58.80±26.48a | 81.41±14.79a |
| 非耐药组 | 156 | 86.58±19.90ab | 85.55±18.98ab | 84.55±19.77ab | 87.63±19.21ab | 86.79±19.25ab | 87.70±19.54a |
| F值 | 88.787 | 86.960 | 94.225 | 104.481 | 115.320 | 15.106 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 6 Comparison of developmental quotient in different functional regions among the three groups
| 组别 | 例数 | 运动能区 | 个人与社会能区 | 语言能区 | 手眼协调能区 | 表现能区 | 实际推理能区c |
|---|---|---|---|---|---|---|---|
| 对照组 | 80 | 101.06±8.26 | 100.34±7.97 | 101.94±9.67 | 102.51±7.08 | 103.28±8.15 | 104.58±8.09 |
| 耐药组 | 94 | 62.20±25.37a | 60.50±28.42a | 60.20±26.74a | 58.03±29.96a | 58.80±26.48a | 81.41±14.79a |
| 非耐药组 | 156 | 86.58±19.90ab | 85.55±18.98ab | 84.55±19.77ab | 87.63±19.21ab | 86.79±19.25ab | 87.70±19.54a |
| F值 | 88.787 | 86.960 | 94.225 | 104.481 | 115.320 | 15.106 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| [1] |
|
| [2] |
左然然, 孙素真. 儿童药物难治性癫痫的遗传学及临床特征分析[J]. 中国全科医学, 2025, 28(6): 756-762. DOI: 10.12114/j.issn.1007-9572.2024.0063.
|
| [3] | |
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
阎泓羽, 冯硕, 刘婉婷, 等. 儿童难治性癫痫术后认知功能变化的研究进展[J]. 中国医学前沿杂志(电子版), 2024, 16(4): 68-72. DOI: 10.12037/YXQY.2024.04-11.
|
| [1] | LI Zihan, LIU Lei, WANG Jiayu, ZHU Xinyu, TIAN Yu. Research Progress on the Application of Virtual Reality Technology in the Management of Childhood and Adolescent Obesity [J]. Chinese General Practice, 2026, 29(33): 4943-4950. |
| [2] | ZHU Rongxin, GAO Tongxun, YUAN Zhenhua, WU Jingjing, TONG Min, NIU Yuhang, REN Xianqing. A Scoping Review of Prediction Models for Renal Injury Risk in Children with Henoch-Schönlein Purpura [J]. Chinese General Practice, 2026, 29(33): 4928-4935. |
| [3] | ZHOU Jiali, JIANG Denan, SHEN Guangdian, LIU Xinyu, ZHU Xuan, ZHA Jindian, ZHANG Ronghua, ZHU Bing, SONG Peige. A Qualitative Study on Identifying Priority Areas of Physical and Mental Comorbidity in Children and Adolescents in Zhejiang Province [J]. Chinese General Practice, 2026, 29(33): 4936-4942. |
| [4] | LI Jing, LIU Ziqi, QIAN Li, YAO Ruiqin. Research Progress on the Role of the Microbiota-gut-brain Axis in Epilepsy [J]. Chinese General Practice, 2026, 29(32): 4821-4826. |
| [5] | ZENG Ling, XIE Leyun, YU Renhe, SONG Lin, ZENG Saizhen. Age-stratified Clinical Characteristics and Risk Factors for Lobar Pneumonia in Children with Mycoplasma Pneumoniae Pneumonia [J]. Chinese General Practice, 2026, 29(32): 4752-4758. |
| [6] | SU Die, ZHANG Yan, CHEN Xiaosong, HAN Yuxia, YAN Yongbin, DUAN Junya, CHEN Xinying, ZHAO Chenghao. Outcome Measures in Randomized Controlled Trials of Traditional Chinese Medicine for Refractory Mycoplasma Pneumoniae Pneumonia in Children [J]. Chinese General Practice, 2026, 29(31): 4609-4618. |
| [7] | ZHANG Xiaozhen, YANG Chengbo, JIN Qianhui, WANG Shuai, ZHOU Jihe. Comparative Study on the Effects of the Computer Assisted Rehabilitation Environment System and Conventional Rehabilitation on Improving Motor Function in Children with Global Developmental Delay [J]. Chinese General Practice, 2026, 29(27): 3938-3946. |
| [8] | GAO Min, DING Ying, HAN Shanshan, XU Yan, WU Ruihong, LI Yudi. Correlation of Selected Blood Biomarkers with 24-hour Urine Protein Excretion in 3 774 Pediatric Patients with IgA Vasculitis Nephritis [J]. Chinese General Practice, 2026, 29(23): 3320-3328. |
| [9] | Expert Group on Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China, Professional Committee on Obesity Control in Women and Children, China Maternal and Child Health Research Association. Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China (Second Edition) [J]. Chinese General Practice, 2026, 29(23): 3233-3252. |
| [10] | MA Linling, WANG Qiqiong, NI Xiaofeng, SHI Yuqing, WEN Yan, PAN Xiangcheng. Construction of a Scientific Popularization Framework for Antibacterial Drugs for Children Discharged from Hospital [J]. Chinese General Practice, 2026, 29(22): 3214-3219. |
| [11] | CHAI Zhihao, ZHANG Weisen, LUO Jiaoling, ZHU Feng, ZHU Tong, JIN Yali, PAN Jing, LU Yingjun, JIANG Chaoqiang. The Mediation Effect of Socioeconomic Status in Childhood Parental Literacy and Cognitive Function in Middle-aged and Older People: Based on Guangzhou Biobank Cohort Study [J]. Chinese General Practice, 2026, 29(21): 2959-2966. |
| [12] | HUANG Haili, LI Yuhong, YU Yang, GUO Ping, HAN Changzheng, LIU Ping. A Mixed Study of Fertility Intention and Its Influencing Factors among the Childbearing-age Women in Anhui Province [J]. Chinese General Practice, 2026, 29(20): 2887-2894. |
| [13] | LIU Xiaoyu, ZHU Rongxin, ZHANG Bo, SU Hang, REN Xianqing. Defining Clinical Questions and Outcome Indicators in Guidelines for Diagnosis and Treatment of Nocturnal Enuresis in Children with Integrated Traditional Chinese and Western Medicine Based on Modified Delphi Method [J]. Chinese General Practice, 2026, 29(15): 2050-2055. |
| [14] | XIONG Xiaoman, LI Aijun, ZHENG Yuehong, YANG Qiuyan, ZHANG Yanli. To Explore the Necessity of Bronchodilation Test in Children with Normal FEV1, FVC and FEV1/FVC but Decreased Small Airway Function [J]. Chinese General Practice, 2026, 29(15): 1992-1997. |
| [15] | SHEN Yong, ZHOU Jingying, WANG Xueping, JIA Meixiang, LIU Jiajia, ZHAN Haojian, WANG Lifang, YAN Hao, PENG Danyuan, YUE Weihua. Construction of Support Services List for Parents of Children with Autism Based on "Timing It Right" Theory [J]. Chinese General Practice, 2026, 29(13): 1688-1698. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||